Market Overview

CLASS ACTION UPDATE for AMPE and NVRO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Share:

NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Ampio Pharmaceuticals, Inc. (NYSEAmerican: AMPE)
Class Period:
December 14, 2017 - August 7, 2018
Lead Plaintiff Deadline: October 24, 2018
Join the action: http://www.zlk.com/pslra-1/ampio-pharmaceuticals-inc-loss-form?wire=3

Allegations: Ampio Pharmaceuticals, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the FDA would find Ampio's AP-003-C Phase 3 clinical trial inadequate and not well-controlled; (2) as a result, Ampio had not successfully completed two pivotal clinical trials for Ampio; (3) consequently, Defendants' public statements were materially false and misleading at all relevant times.

To learn more about the AMPE class action contact jlevi@levikorsinsky.com.

Nevro Corp. (NYSE:NVRO)
Class Period:
January 8, 2018 - July 12, 2018
Lead Plaintiff Deadline: October 22, 2018
Join the action: http://www.zlk.com/pslra-1/nevro-corp-loss-form?wire=3

Allegations: Nevro Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) Nevro had engaged in a fraudulent scheme by using protected confidential and proprietary trade secrets and stolen documents from its competitors to develop and enhance the Company's Senza systems; (2) as a result, the Company's Senza systems were not "novel" or "proprietary;" (3) these practices caused the Company to be vulnerable to increased litigation expenses and adverse legal and regulatory action; (4) as a result, Nevro's U.S. sales growth was not sustainable; and (5) as a result of the foregoing, Defendants' statements about Nevro's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the NVRO class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Primary Logo

View Comments and Join the Discussion!